FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:2591-2602 June 17, 2004 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Rheumatoid arthritis, a chronic, systemic, inflammatory autoimmune disease, has as its primary target the synovial tissues. When the disease is unchecked, it leads to substantial disability and premature death.¹ It affects approximately 0.8 percent of adults worldwide,² is more common in women (by a ratio of 3 to 1), and has an earlier onset in women, frequently beginning in the childbearing years.³ Recent advances in understanding the cytokine networks that are responsible for the ongoing inflammatory response in rheumatoid arthritis⁴ have led to the successful use of therapies that target tumor necrosis factor (TNF-) and interleukin-1.⁵ (These therapies were . . . [Full Text of this Article]

Early Diagnosis and Treatment

General Therapeutic Principles

Medications

NSAIDs

Corticosteroids

Synthetic DMARDs

Biologic DMARDs

Combination Therapy with DMARDs

Initial Treatment

Therapy for Established Rheumatoid Arthritis

Coexisting Illnesses

Current Challenges

Source Information

From the Department of Internal Medicine, University of Nebraska Medical Center; and the Omaha Veterans Affairs Medical Center — both in Omaha.

Address reprint requests to Dr. O'Dell at the Department of Internal Medicine, 983025 Nebraska Medical Center, Omaha, NE 68198-3025, or at jrodell@unmc.edu.

Related Letters:

Rheumatoid Arthritis
Burchini G., Orsi C., Bhattacharya N., O'Dell J. R.
Extract | Full Text | PDF  
N Engl J Med 2004; 351:1360-1361, Sep 23, 2004. Correspondence

New Drugs for Rheumatoid Arthritis
Messori A., Santarlasci B., Vaiani M.
Extract | Full Text | PDF  
N Engl J Med 2004; 351:937-938, Aug 26, 2004. Correspondence

This article has been cited by other articles:

• Yu, J. J., Ruddy, M. J., Conti, H. R., Boonanantanasarn, K., Gaffen, S. L. (2008). The Interleukin-17 Receptor Plays a Gender-Dependent Role in Host Protection against Porphyromonas gingivalis-Induced Periodontal Bone Loss. Infect. Immun. 76: 4206-4213 [Abstract] [Full Text]  
• Kravitz, R. L., Duan, N., White, R. H. (2008). N-of-1 Trials of Expensive Biological Therapies: A Third Way?. Arch Intern Med 168: 1030-1033 [Abstract] [Full Text]  
• Vera-Llonch, M., Massarotti, E., Wolfe, F., Shadick, N., Westhovens, R., Sofrygin, O., Maclean, R., Yuan, Y., Oster, G. (2008). Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. Rheumatology (Oxford) 47: 535-541 [Abstract] [Full Text]  
• Rossi, C. M., Di Comite, G., Babb, R. R., Nori, U. S., Agarwal, A. K., Rovin, B. H., Saag, K. G., Shane, E., Marcus, R. (2008). Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis. NEJM 358: 1302-1304 [Full Text]  
• Baker, D. L., Stroup, J. S., Gilstrap, C. A. (2007). Tophaceous Gout in a Patient With Rheumatoid Arthritis. JAOA: Journal of the American Osteopathic Association 107: 554-556 [Abstract] [Full Text]  
• Verstappen, S M M, Jacobs, J W G, van der Veen, M J, Heurkens, A H M, Schenk, Y, ter Borg, E J, Blaauw, A A M, Bijlsma, J W J, on the behalf of the Utrecht Rheumatoid Arthritis, (2007). Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66: 1443-1449 [Abstract] [Full Text]  
• Oerlemans, R., Vink, J., Dijkmans, B. A C, Assaraf, Y. G, van Miltenburg, M., van der Heijden, J., Ifergan, I., Lems, W. F, Scheper, R. J, Kaspers, G. J L, Cloos, J., Jansen, G. (2007). Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor {alpha} and glucocorticoid induced apoptosis. Ann Rheum Dis 66: 1289-1295 [Abstract] [Full Text]  
• Yamamoto, K., Yamada, R. (2007). Lessons from a Genomewide Association Study of Rheumatoid Arthritis. NEJM 357: 1250-1251 [Full Text]  
• Santora, K., Rasa, C., Visco, D., Steinetz, B. G., Bagnell, C. A. (2007). Antiarthritic Effects of Relaxin, in Combination with Estrogen, in Rat Adjuvant-Induced Arthritis. J. Pharmacol. Exp. Ther. 322: 887-893 [Abstract] [Full Text]  
• Wasko, M. C. M., Hubert, H. B., Lingala, V. B., Elliott, J. R., Luggen, M. E., Fries, J. F., Ward, M. M. (2007). Hydroxychloroquine and Risk of Diabetes in Patients With Rheumatoid Arthritis. JAMA 298: 187-193 [Abstract] [Full Text]  
• Bruce, S. P, Boyce, E. G (2007). Update on Abatacept: A Selective Costimulation Modulator for Rheumatoid Arthritis. The Annals of Pharmacotherapy 41: 1153-1162 [Abstract] [Full Text]  
• O'Dell, J. R. (2007). The BeSt Way to Treat Early Rheumatoid Arthritis?. ANN INTERN MED 146: 459-460 [Full Text]  
• Hildner, K. M., Schirmacher, P., Atreya, I., Dittmayer, M., Bartsch, B., Galle, P. R., Wirtz, S., Neurath, M. F. (2007). Targeting of the Transcription Factor STAT4 by Antisense Phosphorothioate Oligonucleotides Suppresses Collagen-Induced Arthritis. J. Immunol. 178: 3427-3436 [Abstract] [Full Text]  
• Zipris, D., Lien, E., Nair, A., Xie, J. X., Greiner, D. L., Mordes, J. P., Rossini, A. A. (2007). TLR9-Signaling Pathways Are Involved in Kilham Rat Virus-Induced Autoimmune Diabetes in the Biobreeding Diabetes-Resistant Rat. J. Immunol. 178: 693-701 [Abstract] [Full Text]  
• Gaffo, A., Saag, K. G., Curtis, J. R. (2006). Treatment of rheumatoid arthritis. Am J Health Syst Pharm 63: 2451-2465 [Abstract] [Full Text]  
• Fraenkel, L., Rabidou, N., Dhar, R. (2006). Are rheumatologists' treatment decisions influenced by patients' age?. Rheumatology (Oxford) 45: 1555-1557 [Abstract] [Full Text]  
• Resman-Targoff, B. H. (2006). Medical therapy: Where are we now?. Am J Health Syst Pharm 63: S11-S18 [Abstract] [Full Text]  
• Pacher, P., Batkai, S., Kunos, G. (2006). The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacol. Rev. 58: 389-462 [Abstract] [Full Text]  
• Weinblatt, M E, Keystone, E C, Furst, D E, Kavanaugh, A F, Chartash, E K, Segurado, O G (2006). Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 65: 753-759 [Abstract] [Full Text]  
• Summers, K. M, Kockler, D. R (2005). Rituximab Treatment of Refractory Rheumatoid Arthritis. The Annals of Pharmacotherapy 39: 2091-2095 [Abstract] [Full Text]  
• Nell, V P K, Machold, K P, Stamm, T A, Eberl, G, Heinzl, H, Uffmann, M, Smolen, J S, Steiner, G (2005). Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 64: 1731-1736 [Abstract] [Full Text]  
• Cush, J J (2005). Biological drug use: US perspectives on indications and monitoring. Ann Rheum Dis 64: iv18-iv23 [Abstract] [Full Text]  
• Manna, R., Verrecchia, E., Diaco, M., Montalto, M., Cammarota, G., Gasbarrini, G. (2005). Folic acid supplementation during methotrexate treatment: nonsense?. Rheumatology (Oxford) 44: 563-564 [Full Text]  
• Berman, J., Girardi, G., Salmon, J. E. (2005). TNF-{alpha} Is a Critical Effector and a Target for Therapy in Antiphospholipid Antibody-Induced Pregnancy Loss. J. Immunol. 174: 485-490 [Abstract] [Full Text]  
• Burchini, G., Orsi, C., Bhattacharya, N., O'Dell, J. R. (2004). Rheumatoid Arthritis. NEJM 351: 1360-1361 [Full Text]  
• Messori, A., Santarlasci, B., Vaiani, M. (2004). New Drugs for Rheumatoid Arthritis. NEJM 351: 937-938 [Full Text]